Clinical Trials Browser

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06644781 2026-01-12

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Phase 3 Recruiting

510 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05836584 2025-12-01

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Phase 2 Active not recruiting

240 enrolled

Gastrointestinal

Clinical Stage I Gastric Cancer AJCC v8

NCT06313801 2025-11-21

Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions

Phase 2 Recruiting

106 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05383482 2025-11-17

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Phase 1/2 Completed

22 enrolled

GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

NCT06304974 2025-11-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Phase 3 Active not recruiting

497 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Active not recruiting

140 enrolled

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT02495896 2025-11-10

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

61 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Pancreatic Neoplasms

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Phase 1 Active not recruiting

463 enrolled

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT05381038 2025-09-23

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Phase 1/2 Recruiting

10 enrolled

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms, Neoplasms

NCT06531434 2025-09-22

Establishing Best Treatment Strategy for T4 Esophageal Cancer

Phase 1/2 Recruiting

22 enrolled

Gastrointestinal

Esophageal Cancer TNM Staging Primary Tumor (T) T4

NCT06947291 2025-09-08

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Phase 2 Recruiting

350 enrolled

GastrointestinalOther solid neoplasm

Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

NCT05076760 2025-08-29

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Phase 1 Recruiting

40 enrolled

BreastDermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

613 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Phase 1 Completed

185 enrolled 28 charts

GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06732856 2025-07-28

NEO-CLAUD

Phase 1/2 Recruiting

57 enrolled

Gastrointestinal

Stomach Neoplasms

NCT03421288 2025-07-25

DANTE

Phase 2 Active not recruiting

677 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

19 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02039336 2025-07-08

M13DAP

Phase 1/2 Completed

35 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06769425 2025-06-24

HS-10502

Phase 1 Recruiting

157 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT05461794 2025-06-13

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Phase 2 Terminated

96 enrolled 17 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03448835 2025-06-08

PANDA

Phase 2 Active not recruiting

20 enrolled

Gastrointestinal

Stomach Neoplasms

NCT03914443 2025-05-31

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

Phase 1 Completed

37 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04140526 2025-05-23

PRESERVE-001

Phase 1/2 Active not recruiting

733 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT06028737 2025-05-06

OCTASUR

Phase 2/3 Recruiting

150 enrolled

Gastrointestinal

Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms

NCT05919537 2025-04-18

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Phase 1 Active not recruiting

68 enrolled

GastrointestinalThoracic

Fibromatosis, Gingival, 2, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Pancreatic Neoplasms

NCT06914687 2025-04-06

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2 Not yet recruiting

30 enrolled

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Phase 1 Terminated

272 enrolled

GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT04256707 2025-03-19

SPRINT

Phase 1/2 Completed

126 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT01924819 2025-03-04

TOPGEAR

Phase 2/3 Active not recruiting

574 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05296005 2025-02-07

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Phase 1 Withdrawn

Gastrointestinal

Clinical Stage I Gastric Cancer AJCC v8

Clinical Trials

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

TOGAR

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer

ILUSTRO

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

MTAPESTRY 101

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

KEYNOTE-585

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

KEYNOTE-585

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

TroFuse-015

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

A Study of KK2269 in Adult Participants With Solid Tumors

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Establishing Best Treatment Strategy for T4 Esophageal Cancer

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

KEYVIBE-005

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

NEO-CLAUD

DANTE

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

M13DAP

HS-10502

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

PANDA

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

PRESERVE-001

OCTASUR

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

SPRINT

TOPGEAR

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers